Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $46.31, for a total value of $1,157,750.00. Following the sale, the chief executive officer now owns 307,054 shares of the company’s stock, valued at $14,219,670.74. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Janux Therapeutics Stock Performance
NASDAQ JANX opened at $46.25 on Friday. The firm has a market capitalization of $2.40 billion, a P/E ratio of -37.91 and a beta of 3.57. The stock has a 50-day simple moving average of $43.92 and a two-hundred day simple moving average of $44.52. Janux Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $65.60.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The company had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. The firm’s quarterly revenue was up 709.1% on a year-over-year basis. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.
Analyst Ratings Changes
Check Out Our Latest Stock Report on JANX
Institutional Trading of Janux Therapeutics
A number of hedge funds have recently added to or reduced their stakes in JANX. Summit Securities Group LLC purchased a new position in Janux Therapeutics in the second quarter valued at $29,000. Amalgamated Bank grew its position in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares during the period. Plato Investment Management Ltd purchased a new position in shares of Janux Therapeutics in the 2nd quarter valued at about $42,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Janux Therapeutics in the 2nd quarter worth about $151,000. Finally, AQR Capital Management LLC acquired a new position in Janux Therapeutics in the 2nd quarter worth about $215,000. 75.39% of the stock is owned by hedge funds and other institutional investors.
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Featured Stories
- Five stocks we like better than Janux Therapeutics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- 3 Warren Buffett Stocks to Buy Now
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.